# Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ALDX
## Company Profile
- Ticker: ALDX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology, Ophthalmology
## Stock Data
- Close: 1.54 USD
- Market cap: 98926551.52 USD
- Last updated: 2026-09-08
## Business Overview
Aldeyra Therapeutics is a biotechnology company focused on inflammation, ophthalmology, and immune-mediated disease. Its story is built around therapies for conditions where inflammation plays a major role.
## Why The Stock Is Moving

As of Sep 8, 2026, ALDX closed up 4.05% at $1.54. No new same-company headline was identified in the current news window.

## Geographic Base

Aldeyra is headquartered in the United States and listed on NASDAQ. It sits in specialty immunology and ophthalmology biotechnology.

## Business Model

The company depends on clinical data, regulatory progress, and the ability to develop a focused pipeline in challenging inflammatory diseases. Investors usually watch efficacy, safety, and approval milestones.

## Landscape Position

Aldeyra occupies a niche inflammation-and-eye-disease position within biotech. The stock is catalyst-sensitive because a narrow number of data events can meaningfully shift the story.

## Future Catalysts

- Aldeyra’s catalysts are reproxalap and the dry-eye / ophthalmology regulatory path, where the next step can materially move the stock. The company is still very event-driven.

## Recent News
- 2017-05-17 12:00 EST — [Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting](https://biopharmsignal.com/news/ALDX/aldeyra-therapeutics-presents-noninfectious-anterior-uveitis-phase-2-clinical-tr-4f883fdb) — Source: Aldeyra Therapeutics, Inc.
- 2017-05-15 11:30 EST — [Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results](https://biopharmsignal.com/news/ALDX/aldeyra-therapeutics-provides-corporate-update-and-announces-first-quarter-2017--0b02485b) — Source: Aldeyra Therapeutics, Inc.
- 2017-05-08 12:00 EST — [Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results](https://biopharmsignal.com/news/ALDX/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-corporate--3bed263c) — Source: Aldeyra Therapeutics, Inc.
- 2017-04-27 12:00 EST — [Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial](https://biopharmsignal.com/news/ALDX/aldeyra-therapeutics-announces-first-patient-enrolled-in-noninfectious-anterior--e1d57974) — Source: Aldeyra Therapeutics, Inc.
- 2017-04-20 12:00 EST — [Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome](https://biopharmsignal.com/news/ALDX/aldeyra-therapeutics-inc-receives-orphan-drug-designation-from-the-u-s-food-and--7804bcf1) — Source: Aldeyra Therapeutics, Inc.